From: Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy
Application | Main components of vector | Size (nm) | Route | mRNA dosage | Status | References |
---|---|---|---|---|---|---|
mRNA vaccine | ALC-0315 | Not found | I.M. | 30 µg (For humans) | Market | [8] |
SM-102 | Not found | I.M. | 50 µg (For humans) | Market | [26] | |
Cholesterol, phosphatidylserine | < 200 |  S.C. | 12 µg | Completed | [20] | |
Protein replacement | PEG-PAsp(DET) | 100 | I.C.V. | 3 µg | Completed | [85] |
Biodegradable ionizable lipids (ATX) | Undisclosed | I.V. | 2 and 4Â mg/kg | Completed | [86] | |
Phospholipids, cholesterol, PEG | < 100 | I.V. | 190 and 760 ng | Completed | [87] | |
mRNA antibody | DSPC, cholesterol and PEG-lipid | Undisclosed | I.V. | 0.1, 0.3 and 0.6Â mg/kg | Active(Phase I) | [88] |
DOTAP, cholesterol | 183–339 | I.T. | 5 µg | Completed | [89] | |
DSPC, cholesterol and PEG-lipid | 88.99 | I.V. | 0.2 and 1Â mg/kg | Completed | [90] | |
TransIT-mRNA Transfection kit | Undisclosed | I.V. | 5 µg | Completed | [91] | |
Gene delivery and editing | Cationic ionizable lipids, phospholipids, cholesterol | 150 | I.V. | 0.1Â mg/kg | Completed | [92] |
306-O12B (A leading tail-branched bioreducible lipidoid) | 110 | I.V. | 3Â mg/kg | Completed | [93] |